Brought to you by 
Receptor BioLogix closes $33.6mm Series A round
30 Mar 2021
Executive Summary
Receptor BioLogix (protein therapeutics for cancer and autoimmune and metabolic disorders) brought in $33.6mm with its Series A financing round led by Skyline Ventures. Other participants were Domain Associates, Essex Woodlands Health Ventures, MedImmune Ventures, Takeda Research Investment, and Northwest Technology Ventures.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Receptor BioLogix closes $33.6mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice